Drug intelligence / Profile preview

BNT162b7 Bivalent

Development stage: Unknown
Lead developer: BioNTech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**BNT162b7 Bivalent** is an investigational BioNTech RNA-based COVID-19 booster vaccine candidate evaluated with Pfizer in the C4591044 clinical study. It is a bivalent SARS-CoV-2 vaccine designed to encode spike antigens from the original SARS-CoV-2 strain and the Omicron BA.4/BA.5 sublineages, with the objective of broadening immune responses against circulating Omicron-related variants. The candidate was administered as a single 30 microgram booster dose in adults previously vaccinated with an authorized mRNA COVID-19 vaccine.

Other names: BNT162b7 Bivalent (Original/OMI BA.4/BA.5)BNT162b7 Bivalent (WT/OMI BA.4/BA.5)

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on BNT162b7 Bivalent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT162b7 Bivalent.

Explore the full profile